Literature DB >> 12065058

Drug-metabolizing activity of human and rat liver, lung, kidney and intestine slices.

R De Kanter1, M H De Jager, A L Draaisma, J U Jurva, P Olinga, D K F Meijer, G M M Groothuis.   

Abstract

1. Organ-specific biotransformation was studied in human and rat liver, lung, kidney and small intestine slices and compared on a protein basis, using four model substances. 2. Deethylation of lidocaine was highest in liver slices from both man and rat, followed by the small intestine. 3. Metabolism of testosterone was highest in liver slices, but a different overall metabolic pattern was found between the different organs. 4. Lung, kidney and intestine slices prepared from human and rat organs showed mainly an unknown metabolite of 7-ethoxycoumarin identified as 4-ethoxy-2-hydroxyphenyl propionic acid (EPPA). 5. The maximal metabolism of 7-ethoxycoumarin in slices was equal with in vivo V(max) in the rat. 6. Phase II metabolism of 7-hydroxycoumarin in kidney and intestinal slices was about 60% of the activity in liver slices. 7. In conclusion, organs other than the liver show a surprisingly high drug-metabolizing activity. Thus, the use of precision-cut slices of a combination of drug metabolizing organs in an in vitro test system from both animal and human origin is required for a proper systematic prediction of drug metabolism in man.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12065058     DOI: 10.1080/00498250110112006

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  8 in total

1.  Preparation and incubation of precision-cut liver and intestinal slices for application in drug metabolism and toxicity studies.

Authors:  Inge A M de Graaf; Peter Olinga; Marina H de Jager; Marjolijn T Merema; Ruben de Kanter; Esther G van de Kerkhof; Geny M M Groothuis
Journal:  Nat Protoc       Date:  2010-08-19       Impact factor: 13.491

2.  Metabolomic studies in the inborn error of metabolism alkaptonuria reveal new biotransformations in tyrosine metabolism.

Authors:  Brendan P Norman; Andrew S Davison; Juliette H Hughes; Hazel Sutherland; Peter Jm Wilson; Neil G Berry; Andrew T Hughes; Anna M Milan; Jonathan C Jarvis; Norman B Roberts; Lakshminarayan R Ranganath; George Bou-Gharios; James A Gallagher
Journal:  Genes Dis       Date:  2021-02-22

3.  An in vitro method of alcoholic liver injury using precision-cut liver slices from rats.

Authors:  Lynell W Klassen; Geoffrey M Thiele; Michael J Duryee; Courtney S Schaffert; Amy L DeVeney; Carlos D Hunter; Peter Olinga; Dean J Tuma
Journal:  Biochem Pharmacol       Date:  2008-05-21       Impact factor: 5.858

Review 4.  Best Practices and Progress in Precision-Cut Liver Slice Cultures.

Authors:  Liza Dewyse; Hendrik Reynaert; Leo A van Grunsven
Journal:  Int J Mol Sci       Date:  2021-07-01       Impact factor: 5.923

5.  Elucidating Organ-Specific Metabolic Toxicity Chemistry from Electrochemiluminescent Enzyme/DNA Arrays and Bioreactor Bead-LC-MS/MS.

Authors:  Dhanuka P Wasalathanthri; Dandan Li; Donghui Song; Zhifang Zheng; Dharamainder Choudhary; Ingela Jansson; Xiuling Lu; John B Schenkman; James F Rusling
Journal:  Chem Sci       Date:  2015       Impact factor: 9.825

6.  Protective effects of phenolic acids on mercury-induced DNA damage in precision-cut kidney slices.

Authors:  Irma Edith Carranza-Torres; Ezequiel Viveros-Valdez; Nancy Elena Guzmán-Delgado; Sara García-Davis; Javier Morán-Martínez; Nadia Denys Betancourt-Martínez; Isaías Balderas-Rentería; Pilar Carranza-Rosales
Journal:  Iran J Basic Med Sci       Date:  2019-04       Impact factor: 2.699

Review 7.  Assessment of immunotoxicity using precision-cut tissue slices.

Authors:  Katherina Sewald; Armin Braun
Journal:  Xenobiotica       Date:  2012-11-16       Impact factor: 1.908

8.  Cytochrome P450-mediated drug interactions in COVID-19 patients: Current findings and possible mechanisms.

Authors:  Mahmoud A El-Ghiaty; Sherif M Shoieb; Ayman O S El-Kadi
Journal:  Med Hypotheses       Date:  2020-06-26       Impact factor: 1.538

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.